# Engineered Immune Cells for T1D

> **NIH NIH R01** · STANFORD UNIVERSITY · 2024 · $767,617

## Abstract

Project Summary / Abstract
This application is in response to a specific request for proposals to develop immune cell engineering towards
the treatment of type 1 diabetes (T1D). We propose to evaluate genetic engineering approaches in immune T
regulatory cells (Treg) by integrating chimeric antigen receptor (CAR) proteins that are engineered with an
external targeting domain (scFv) and internal stimulatory domain. This approach has revolutionized cancer cell
therapy with heightened specificity and effectiveness of T cell action. We and others have found evidence that
CAR Treg can help mediate immune protection of islets and may even act upon islets themselves to reduce
stress and cell death. We propose to (a) determine how enhanced targeting and activation of Treg to human
islets might improve islet function and local immune modulation to protect islets, (b) evaluate a method for
enhanced islet targeting through the development and testing of a dual-targeting CAR system that exploits
downstream T cell receptor signaling molecules that have not been previously evaluated and (c) determine
how enhanced targeting and activation of Treg to human monocytes might result in more immunoregulatory
monocytes that could help to alter response to islet autoantigens and prevent immune destruction. One very
important component of our proposal is that we suspect that CAR Treg from patients with T1D may not
function as well as CAR Treg from normal individuals. In fact, there is no data about this available. We think
that some CAR Treg from some T1D patients might be more cytotoxic, less effective or more inflammatory and
we propose to evaluate if this is true statistically and also to develop an approach to introduce and overexpress
a set of genes known to be important for Treg function as a way of making sure that all Treg in all cases will
exert effects that are wanted. We postulate that developing these Treg methods will produce novel clinical
strategies to prevent T1D in high risk patients and to suppress autoimmunity and preserve β-cell mass in
patients with recent-onset T1D.

## Key facts

- **NIH application ID:** 10812410
- **Project number:** 5R01DK132549-03
- **Recipient organization:** STANFORD UNIVERSITY
- **Principal Investigator:** EVERETT MEYER
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $767,617
- **Award type:** 5
- **Project period:** 2022-04-01 → 2026-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10812410

## Citation

> US National Institutes of Health, RePORTER application 10812410, Engineered Immune Cells for T1D (5R01DK132549-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10812410. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*